SCHEMBL21807151

SCHEMBL21807151

N#CC(O)c1cccc(I)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
SLC6A3 Q01959 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP3A4 P08684 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
KCNH2 Q12809 2/20 0.36
CTSB P07858 1/20 0.35
TRPA1 O75762 1/20 0.33
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32
APP P05067 1/20 0.32
PGK1 P00558 1/20 0.31
PGK2 P07205 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
THPO P40225 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8658118 0.79 TRPA1 (0.35) TSHRESR1ESR2SLC6A3CYP2D6
SCHEMBL9256909 0.78 ESR1 (0.59) TSHRESR1ESR2SLC6A3CYP3A4
SCHEMBL7262478 0.78 ESR1 (0.59) TSHRESR1ESR2SLC6A3CYP3A4
SCHEMBL3496129 0.78 ESR1 (0.59) TSHRESR1ESR2SLC6A3CYP3A4
SCHEMBL11605816 0.76 CYP2D6 (0.47) SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL9016042 0.76 CYP2D6 (0.41) SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL2491629 0.76 CYP2D6 (0.41) SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL9176673 0.76 TSHR (0.57) TSHRESR1ESR2CTSB
SCHEMBL6691199 0.76 TSHR (0.57) TSHRESR1ESR2CYP3A4CYP1A2
SCHEMBL198178 0.76 TSHR (0.57) TSHRESR1ESR2SLC6A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 TSHR 4189/4885ESR1 2315/4885ESR2 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.